Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Albano WA, Recabaren JA, Lynch HT, Campbell AS, Mailliard JA, Organ CH, Lynch JF, Kimberling WJ (1982) Natural history of hereditary cancer of the breast and colon. Cancer 50:360–363
Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155–168
Anderson DE, Badzioch MD (1985) Bilaterality in familial breast cancer patients. Cancer 56:2092–2098
Ansquer Y, Gautier C, Fourquet A, Asselain B, Stoppa-Lyonnet D (1998) Survival in early-onset BRCA1 breast-cancer patients. Institute curie breast cancer group. Lancet 352:541
Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK (2008) Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26:4282–4288
Basu SK, Schwartz C, Fisher SG, Hudson MM, Tarbell N, Muhs A, Marcus KJ, Mendenhall N, Mauch P, Kun LE, Constine LS (2008) Unilateral and bilateral breast cancer in women surviving pediatric Hodgkin’s disease. Int J Radiat Oncol Biol Phys 72:34–40
Bernstein JL, Thompson WD, Risch N, Holford TR (1992) The genetic epidemiology of second primary breast cancer. Am J Epidemiol 136:937–948
Breast Cancer Information Core (BIC) Database. http://research.nhgri.nih.gov/bic/
Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94:1365–1372
Bunyan DJ, Eccles DM, Sillibourne J, Wilkins E, Thomas NS, Shea-Simonds J, Duncan PJ, Curtis CE, Robinson DO, Harvey JF, Cross NC (2004) Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification. Br J Cancer 91:1155–1159
Chappuis PO, Nethercot V, Foulkes WD (2000) Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol 18:287–295
Chen W, Pan K, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Lu Y, You W, Xie Y (2008) BRCA1 germline mutations and tumor characteristics in Chinese women with familial or early-onset breast cancer. Breast Cancer Res Treat
Claus EB, Petruzella S, Matloff E, Carter D (2005) Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA 293:964–969
Eisinger F, Stoppa-Lyonnet D, Longy M, Kerangueven F, Noguchi T, Bailly C, Vincent-Salomon A, Jacquemier J, Birnbaum D, Sobol H (1996) Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 56:471–474
Fackenthal JD, Olopade OI (2007) Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 7:937–948
Fatouros M, Baltoyiannis G, Roukos DH (2008) The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol 15:21–33
Fine RE, Whitworth PW, Kim JA, Harness JK, Boyd BA, Burak WE Jr (2003) Low-risk palpable breast masses removed using a vacuum-assisted hand-held device. Am J Surg 186:362–367
Foulkes WD, Chappuis PO, Wong N, Brunet JS, Vesprini D, Rozen F, Yuan ZQ, Pollak MN, Kuperstein G, Narod SA, Begin LR (2000) Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann Oncol 11:307–313
Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20:1480–1490
Gayther SA, Russell P, Harrington P, Antoniou AC, Easton DF, Ponder BA (1999) The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. Am J Hum Genet 65:1021–1029
Gogas J, Markopoulos C, Skandalakis P, Gogas H (1993) Bilateral breast cancer. Am Surg 59:733–735
Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652–5657
Hartman M, Czene K, Reilly M, Bergh J, Lagiou P, Trichopoulos D, Adami HO, Hall P (2005) Genetic implications of bilateral breast cancer: a population based cohort study. Lancet Oncol 6:377–382
Hogervorst FB, Nederlof PM, Gille JJ, McElgunn CJ, Grippeling M, Pruntel R, Regnerus R, van Welsem T, van Spaendonk R, Menko FH, Kluijt I, Dommering C, Verhoef S, Schouten JP, van’t Veer LJ, Pals G (2003) Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res 63:1449–1453
Hwang ES, McLennan JL, Moore DH, Crawford BB, Esserman LJ, Ziegler JL (2007) Ductal carcinoma in situ in BRCA mutation carriers. J Clin Oncol 25:642–647
Imyanitov EN, Hanson KP (2003) Molecular pathogenesis of bilateral breast cancer. Cancer Lett 191:1–7
Jakubowska A, Nej K, Huzarski T, Scott RJ, Lubinski J (2002) BRCA2 gene mutations in families with aggregations of breast and stomach cancers. Br J Cancer 87:888–891
Johannsson O, Loman N, Moller T, Kristoffersson U, Borg A, Olsson H (1999) Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers. Eur J Cancer 35:1248–1257
Johannsson OT, Idvall I, Anderson C, Borg A, Barkardottir RB, Egilsson V, Olsson H (1997) Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 33:362–371
John EM, Miron A, Gong G, Phipps AI, Felberg A, Li FP, West DW, Whittemore AS (2007) Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA 298:2869–2876
Kirchhoff T, Satagopan JM, Kauff ND, Huang H, Kolachana P, Palmer C, Rapaport H, Nafa K, Ellis NA, Offit K (2004) Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. J Natl Cancer Inst 96:68–70
Kwong A, Cheung PS, Wong AY, Hung GT, Lo G, Tsao M, Chan EW, Wong T, Ma M (2008) The acceptance and feasibility of breast cancer screening in the east. Breast 17:42–50
Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, Storfer-Isser A, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BA, Ford D, Peto J, Stoppa-Lyonnet D, Bignon YJ, Struewing JP, Spurr NK, Bishop DT, Klijn JG, Devilee P, Cornelisse CJ, Lasset C, Lenoir G, Barkardottir RB, Egilsson V, Hamann U, Chang-Claude J, Sobol H, Weber B, Stratton MR, Easton DF (1998) Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90:1138–1145
Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, Casilla C, Fazzari M, Srivastava N, Yeung HW, Humm JL, Guillem J, Downey R, Karpeh M, Cohen AE, Ginsberg R (1999) Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging 2:159–171
Li N, Zhang X, Cai Y, Xu X, Zhang L, Pan KF, Wu LY, Wang MR (2006) BRCA1 germline mutations in Chinese patients with hereditary breast and ovarian cancer. Int J Gynecol Cancer 16(Suppl 1):172–178
Li SS, Tseng HM, Yang TP, Liu CH, Teng SJ, Huang HW, Chen LM, Kao HW, Chen JH, Tseng JN, Chen A, Hou MF, Huang TJ, Chang HT, Mok KT, Tsai JH (1999) Molecular characterization of germline mutations in the BRCA1 and BRCA2 genes from breast cancer families in Taiwan. Hum Genet 104:201–204
Lucassen A, Watson E, Eccles D (2001) Evidence based case report: advice about mammography for a young woman with a family history of breast cancer. BMJ 322:1040–1042
Lynch HT, Deters CA, Snyder CL, Lynch JF, Villeneuve P, Silberstein J, Martin H, Narod SA, Brand RE (2005) BRCA1 and pancreatic cancer: pedigree findings and their causal relationships. Cancer Genet Cytogenet 158:119–125
Moran MS, Yang Q, Harris LN, Jones B, Tuck DP, Haffty BG (2008) Long-term outcomes and clinicopathologic differences of African-American versus white patients treated with breast conservation therapy for early-stage breast cancer. Cancer 113:2565–2574
Moslehi R, Chu W, Karlan B, Fishman D, Risch H, Fields A, Smotkin D, Ben-David Y, Rosenblatt J, Russo D, Schwartz P, Tung N, Warner E, Rosen B, Friedman J, Brunet JS, Narod SA (2000) BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 66:1259–1272
Ng R, Pond GR, Tang PA, MacIntosh PW, Siu LL, Chen EX (2008) Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006. Ann Oncol 19:481–486
Niell BL, Rennert G, Bonner JD, Almog R, Tomsho LP, Gruber SB (2004) BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst 96:15–21
Noguchi S, Kasugai T, Miki Y, Fukutomi T, Emi M, Nomizu T (1999) Clinicopathologic analysis of BRCA1- or BRCA2-associated hereditary breast carcinoma in Japanese women. Cancer 85:2200–2205
Petit JY, Veronesi U, Luini A, Orecchia R, Rey PC, Martella S, Didier F, De Lorenzi F, Rietjens M, Garusi C, Sonzogni A, Galimberti V, Leida E, Lazzari R, Giraldo A (2005) When mastectomy becomes inevitable: the nipple-sparing approach. Breast 14:527–531
Porter DE, Cohen BB, Wallace MR, Smyth E, Chetty U, Dixon JM, Steel CM, Carter DC (1994) Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12–21. Br J Surg 81:1512–1515
Ramus SJ, Harrington PA, Pye C, DiCioccio RA, Cox MJ, Garlinghouse-Jones K, Oakley-Girvan I, Jacobs IJ, Hardy RM, Whittemore AS, Ponder BA, Piver MS, Pharoah PD, Gayther SA (2007) Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer. Hum Mutat 28:1207–1215
Robson M, Levin D, Federici M, Satagopan J, Bogolminy F, Heerdt A, Borgen P, McCormick B, Hudis C, Norton L, Boyd J, Offit K (1999) Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst 91:2112–2117
Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA (2008) Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 14:8010–8018
Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30:e57
Sellner LN, Taylor GR (2004) MLPA and MAPH: new techniques for detection of gene deletions. Hum Mutat 23:413–419
Seynaeve C, Verhoog LC, van de Bosch LM, van Geel AN, Menke-Pluymers M, Meijers-Heijboer EJ, van den Ouweland AM, Wagner A, Creutzberg CL, Niermeijer MF, Klijn JG, Brekelmans CT (2004) Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy. Eur J Cancer 40:1150–1158
Silva E, Gatalica Z, Snyder C, Vranic S, Lynch JF, Lynch HT (2008) Hereditary breast cancer: part II. Management of hereditary breast cancer: implications of molecular genetics and pathology. Breast J 14:14–24
Smith KL, Adank M, Kauff N, Lafaro K, Boyd J, Lee JB, Hudis C, Offit K, Robson M (2007) BRCA mutations in women with ductal carcinoma in situ. Clin Cancer Res 13:4306–4310
Sng KW, Ng EH, Ng FC, Tan PH, Low SC, Chiang G, Ho GH, Ng LT, Wilde C, Tan KP (2000) Spectrum of abnormal mammographic findings and their predictive value for malignancy in Singaporean women from a population screening trial. Ann Acad Med Singapore 29:457–462
Song CG, Hu Z, Yuan WT, Di GH, Shen ZZ, Huang W, Shao ZM (2005) Mutational analysis of BRCA1 and BRCA2 genes in early-onset breast cancer patients in Shanghai. Zhonghua Yi Xue Za Zhi 85:3030–3034
Song CG, Hu Z, Yuan WT, Di GH, Shen ZZ, Huang W, Shao ZM (2006) BRCA1 and BRCA2 gene mutations of familial breast cancer from Shanghai in China. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 23:27–31
Suter NM, Ray RM, Hu YW, Lin MG, Porter P, Gao DL, Zaucha RE, Iwasaki LM, Sabacan LP, Langlois MC, Thomas DB, Ostrander EA (2004) BRCA1 and BRCA2 mutations in women from Shanghai China. Cancer Epidemiol Biomarkers Prev 13:181–189
Tiling R, Linke R, Untch M, Richter A, Fieber S, Brinkbaumer K, Tatsch K, Hahn K (2001) 18F-FDG PET and 99mTc-sestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: a comparative study. Eur J Nucl Med 28:711–720
van der Groep P, Bouter A, van der Zanden R, Siccama I, Menko FH, Gille JJ, van Kalken C, van der Wall E, Verheijen RH, van Diest PJ (2006) Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data. J Clin Pathol 59:611–617